Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,809 | 436 | 3,246 |
| Samples | 1,552 | 253 | 1,276 |
| Peptides | 1,223 | 192 | 1,052 |
Function
SCN10A · Sodium voltage-gated channel alpha subunit 10
The protein encoded by this gene is a tetrodotoxin-resistant voltage-gated sodium channel alpha subunit. The properties of the channel formed by the encoded transmembrane protein can be altered by interaction with different beta subunits. This protein may be involved in the onset of pain associated with peripheral neuropathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2014].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000449082 | Q9Y5Y9 | 1,975 | 1,211 |
| ENST00000643924 | A0A2R8Y6J6* | 1,831 | 1,166 |
| ENST00000655275 | A0A590UJM0* | 3 | 3 |
Gene Properties
Recurrent Mutations
All 1211 amino-acid changes on canonical ENST00000449082 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SCN10A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SCN10A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 41/210 20% | 315/1899 17% |
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| Glioblastoma | 9/98 9% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 50/612 8% |
| Non-Small Cell Lung Carcinoma | 38/304 12% | 93/1390 7% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 8/133 6% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 45/810 6% |
| Other Solid Cancers | 4/94 4% | 84/1515 6% |
| Colorectal Carcinoma | 37/143 26% | 147/3239 5% |
| Gastric Carcinoma | 2/74 3% | 93/1809 5% |
| Small Cell Lung Carcinoma | 0/9 0% | 34/752 5% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Esophageal Carcinoma | 3/23 13% | 20/769 3% |
| Germ Cell Tumour | 2/25 8% | 3/169 2% |
| Neuroendocrine Tumour | 9/154 6% | 9/577 2% |
| Osteosarcoma | 4/45 9% | 1/166 1% |
| Bladder Carcinoma | 0/58 0% | 24/956 3% |
| Plasma Cell Myeloma | 1/44 2% | 7/305 2% |
| Ovarian Carcinoma | 7/109 6% | 18/998 2% |
| Other Sarcomas | 3/69 4% | 12/699 2% |
| Hepatocellular Carcinoma | 2/46 4% | 41/2210 2% |
| Head and Neck Carcinoma | 2/85 2% | 29/1574 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Pancreatic Carcinoma | 8/89 9% | 22/1611 1% |
| Cervical Carcinoma | 0/35 0% | 8/422 2% |
| Non-Cancerous | 0/104 0% | 15/830 2% |
| Breast Carcinoma | 5/144 3% | 48/3264 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 35/2550 1% |
Mutation Distribution
Where SCN10A is mutated · all tissues, split by cell line vs tissue
How many mutations in SCN10A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 11 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,809 mutations in SCN10A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|